The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis

Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance

“…Several studies have reported alterations in melatonin levels in MS patients, showing impaired rhythms and decreased nocturnal levels of both serum melatonin (Akpinar et al, 2008) and its main metabolite in urine, 6-sulphatoxymelatonin (6-SMT) Damasceno et al, 2015;Melamud et al, 2012, that are corrected by IFNb or natalizumab treatments (Melamud et al, 2012;Bahamonde et al, 2014). Altered levels of melatonin or 6-SMT are associated with the severity of the disease (Damasceno et al, 2015), and also with fatigue (Damasceno et al, 2015;Melamud et al, 2012), insomnia (Melamud et al, 2012) and depression (Akpinar et al, 2008).…”

Multiple Facets of Melatonin in Immunity: Clinical Applications

“…Besides melatonin actions over the course of the disease, endogenous melatonin has been related to the clinical complications of MS. Thus, serum melatonin levels inversely correlate with depression in MS patients [ 190 ]. Additionally, diurnal vision impairment related to MS was shown to be linked to melatonin circadian rhythm, and more importantly, it was improved by oral treatment with melatonin [ 191 ].…”

Immunomodulation of Potent Antioxidant Agents: Preclinical Study to Clinical Application in Multiple Sclerosis

“…A clinical study by Akpinar et al revealed that nocturnal serum melatonin levels were associated with major depression in acute MS patients, suggesting that melatonin deficiency may contribute to the occurrence of depression in MS patients [Akpinar et al, 2008b]. Moreover, Anderson et al demonstrated that the optimization of melatonin and vitamin D3 inhibits the effects of IL-18 on the symptoms and cell loss of MS, as well as microglia and Tcell activation [Anderson and Rodriguez, 2011].…”